Market capitalization | $4.58b |
Enterprise Value | $4.69b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.47 |
P/S ratio (TTM) P/S ratio | 7.29 |
P/B ratio (TTM) P/B ratio | 17.32 |
Revenue growth (TTM) Revenue growth | 240.74% |
Revenue (TTM) Revenue | $628.79m |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
18 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:
18 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 629 629 |
241%
241%
|
|
Gross Profit | 542 542 |
231%
231%
|
|
EBITDA | -311 -311 |
49%
49%
|
EBIT (Operating Income) EBIT | -313 -313 |
49%
49%
|
Net Profit | -333 -333 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Head office | United States |
CEO | Cedric Francois |
Employees | 706 |
Founded | 2009 |
Website | www.apellis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.